阻断 CD19 CAR-T 细胞上的 CD30 增强其抗 B 细胞白血病/淋巴瘤的功能能力 Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma. PubMed 2026/04/30 发表Front ImmunolQ1 · IF 7(JCR 2025) 靶点:CD19靶点:CD20靶点:CD30技术:CAR-T技术:双特异性抗体淋巴瘤白血病
同步自体移植与 CD19 CAR-T 细胞二线治疗序贯 CD20 × CD3 双特异性抗体治疗难治性伯基特淋巴瘤:病例报告 Simultaneous auto-transplant and CD19 CAR T-cell 2nd line therapy followed by CD20 × CD3 bispecific antibody for refractory Burkitt lymphoma, a case r PubMed 2025/12/08 发表Leuk LymphomaQ3 · IF 2.1(JCR 2025) 靶点:CD19靶点:CD20技术:CAR-T技术:双特异性抗体淋巴瘤白血病
tafasitamab 在滤泡性淋巴瘤中日益凸显的作用 The emerging role of tafasitamab in follicular lymphoma. PubMed 2025/10/15 发表Leuk LymphomaQ3 · IF 2.1(JCR 2025) 靶点:CD19靶点:CD20技术:CAR-T技术:双特异性抗体弥漫大B细胞淋巴瘤滤泡性淋巴瘤白血病
靶向 LILRB1 的 CAR-T 细胞用于血液系统恶性肿瘤治疗 LILRB1-directed CAR-T cells for the treatment of hematological malignancies. PubMed 2025/04/05 发表LeukemiaQ1 · IF 8.8(JCR 2025) 靶点:CD19靶点:CD20技术:CAR-T急性淋巴细胞白血病急性髓系白血病非霍奇金淋巴瘤
靶向 B 细胞急性淋巴细胞白血病和 B 细胞非霍奇金淋巴瘤的双靶向 CAR-T 细胞 Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. PubMed 2025/02/25 发表Blood AdvQ1 · IF 7.7(JCR 2025) 靶点:CD19靶点:CD20靶点:CD22技术:CAR-T急性淋巴细胞白血病非霍奇金淋巴瘤
Ph- 急性淋巴细胞白血病:一线治疗中的免疫治疗 Ph- ALL: immunotherapy in upfront treatment. PubMed 2024/12/06 发表Hematology Am Soc Hematol Educ ProgramQ1 · IF 3.7(JCR 2025) 人群:成人靶点:CD19靶点:CD20技术:双特异性抗体急性淋巴细胞白血病地区:欧洲
CD20 双特异性抗体在淋巴瘤体外模型与 CLL 体内模型中改善对 CD19-CAR-T 细胞的应答 CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models. PubMed 2024/08/15 发表BloodQ1 · IF 23.9(JCR 2025) 靶点:CD19靶点:CD20技术:CAR-T技术:双特异性抗体慢性淋巴细胞白血病淋巴瘤
慢性淋巴细胞白血病的创新联合方案、细胞治疗和双特异性抗体:叙述性综述 Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review. PubMed 2024/03/26 发表Cancers (Basel)Q2 · IF 4.8(JCR 2025) 靶点:CD19靶点:CD20技术:CAR-T技术:双特异性抗体慢性淋巴细胞白血病地区:欧洲
阿西米尼维持抗白血病原始细胞的抗体依赖细胞介导的细胞毒性 Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts. PubMed 2024/03/26 发表Cancers (Basel)Q2 · IF 4.8(JCR 2025) 靶点:CD19靶点:CD20靶点:CD22技术:NK 细胞急性淋巴细胞白血病地区:欧洲
单次高强度运动增强利妥昔单抗在体外对人慢性淋巴细胞白血病 B 细胞的疗效 A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo. PubMed 2024/03/17 发表Brain Behav ImmunQ1 · IF 7.5(JCR 2025) 靶点:CD19靶点:CD20靶点:CD5技术:NK 细胞慢性淋巴细胞白血病地区:欧洲